Related news from
Fri, 14 Aug 2026 07:01:00 +0000	5 Insightful Analyst Questions From Cencora’s Q2 Earnings Call Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a positive market response. Management credited execution in specialty pharmaceuticals, especially through its Management Services Organizations (MSOs) like OneOncology and RCA, as a core driver of growth, while digital transformation initiatives improved operational efficiency. CEO Robert Mauch highlighted the company’s unique positioning in
Wed, 12 Aug 2026 19:58:41 +0000	Sector Update: Healthcare Stocks Advance Late Afternoon Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t
Wed, 12 Aug 2026 15:14:45 +0000	Cencora (COR) Q3 2026 Earnings Call Transcript Revenue hit $84.8 billion as GLP-1 sales surged 25% despite manufacturer price headwinds.
Wed, 12 Aug 2026 14:15:56 +0000	Is Wall Street Bullish or Bearish on Cencora Stock? Cencora has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.
Thu, 06 Aug 2026 11:04:13 +0000	Cencora Q3 Earnings Call Highlights Cencora (NYSE:COR) reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook. Adjusted operating
Wed, 05 Aug 2026 21:06:10 +0000	Cencora Inc (COR) (Q3 2026) Earnings Call Highlights: Strong Double-Digit Growth and Raised Guidance Cencora Inc (COR) delivered 17% adjusted operating income growth and raised its full-year EPS outlook, driven by robust specialty performance and strategic share repurchases.
Fri, 14 Aug 2026 12:06:01 +0000	Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]
Thu, 06 Aug 2026 03:04:18 +0000	Cencora, Inc. Q3 2026 Earnings Call Summary Moby summary of Cencora, Inc.'s Q3 2026 earnings call
Fri, 14 Aug 2026 19:46:29 +0000	AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.
Thu, 13 Aug 2026 08:09:06 +0000	US Stock Market Today: S&P 500 Futures Edge Up As Traders Eye Key CPI The Morning Bull - US Market Morning Update Thursday, Aug, 13 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.2% and Nasdaq-100 futures ahead by roughly 0.6%, as investors focus on a key inflation update and what it could mean for interest rates. July CPI is expected at 3.4% year on year, with core inflation seen at 2.5%, which would suggest the cost of living is still rising but closer to the central bank’s comfort zone. At the same...
Wed, 12 Aug 2026 20:14:41 +0000	US Equity Markets End Mixed Amid Tech Stock Gains, Lower Inflation Data US equity indexes ended mixed Wednesday amid stock gains by some major technology stocks and a four-
Tue, 11 Aug 2026 13:16:16 +0000	S&P 500 Medical Stocks: Three Trade Near Buy Points; One Rallies Despite Mixed Results S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three.
Fri, 07 Aug 2026 20:44:57 +0000	AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.
Fri, 07 Aug 2026 18:20:00 +0000	Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results? Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.
Thu, 06 Aug 2026 11:10:00 +0000	Camino Announces $5.0 Million Brokered Private Placement of Units and Concurrent $9.5 Million Non-Brokered Private Placement of Convertible Debentures "Not for distribution to United States news wire services or for dissemination in the United States." VANCOUVER, BC / ACCESS Newswire / August 6, 2026 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased ...
Tue, 11 Aug 2026 20:47:01 +0000	AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026? AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!